Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
NCAM-1/CD56 Antibody (RNL-1), DyLight 350, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP197717UV
Description
NCAM-1/CD56 Monoclonal specifically detects NCAM-1/CD56 in Human, Mouse samples. It is validated for Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen.Specifications
NCAM-1/CD56 | |
Monoclonal | |
DyLight 350 | |
CD56, CD56 NCAM-1, CD56 antigen, MSK39, N-CAM-1, NCAM-1, NCAMantigen recognized by monoclonal 5.1H11, neural cell adhesion molecule 1, neural cell adhesion molecule, NCAM | |
Mouse | |
Affinity Purified | |
RUO | |
Primary | |
RNL-1 was defined as a cluster I antibody during the Second International Workshop on Small Cell Lung Cancer (SCLC) Antibodies. RNL-1 recognizes NCAM which is present in small cell lung cancer (SCLC) and lung carcinoids. | |
Store at 4C in the dark. |
Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), Immunohistochemistry (Frozen) | |
RNL-1 | |
Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen | |
NCAM1 | |
Clone RNL-1 is a mouse monoclonal IgG1 antibody derived by fusion of SP2/0-Ag14 mouse myeloma cells with spleen cells from a BALB/c mouse immunized with the small cell lung cancer cell line NCI-H82. | |
0.1 mL | |
Astrocyte Markers, Cellular Markers, Cytokine Research, Cytoskeleton Markers, Growth and Development, Hematopoietic Stem Cell Markers, Immunology, Innate Immunity, Membrane Vesicle Markers, Neuronal Cell Markers, Neuronal Stem Cell Markers, Neuroscience, Stem Cell Markers | |
4684 | |
Human, Mouse | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction